Abstract
The management of multiple sclerosis (MS) is changing, and for the first time treatments which appear to influence the course of the disease are becoming available. This article examines our current understanding of MS pathogenesis and assesses which, if any, of the emerging therapies are likely to make an impact on this potentially disabling condition.
| Original language | English |
|---|---|
| Pages (from-to) | 137-40 |
| Number of pages | 4 |
| Journal | The British Journal of Hospital Medicine |
| Volume | 57 |
| Issue number | 4 |
| Publication status | Published - 4 Feb 1997 |
Keywords
- Adrenal Cortex Hormones
- Demyelinating Diseases
- Humans
- Infusions, Intravenous
- Interferon-beta
- Methylprednisolone
- Multiple Sclerosis
- Placebos
- Randomized Controlled Trials as Topic